Metabolomics Lunge


In pulmonary hypertension (PH; = pulmonary hypertension), functional, disease-specific biomarkers are crucial for better management of this severe haemodynamic disease. The current diagnosis of PH is difficult and invasive, therefore alternative and non-invasive diagnostic markers are being sought. This research project will investigate metabolites in the lungs for the diagnosis of PH. The research area of metabolomics focuses on the analysis and profiling of unique chemical biomarkers (metabolites) such as free fatty acids (FFA) and lipids. By using advanced analytical techniques such as mass spectrometry and nuclear magnetic resonance (NMR), researchers can gain valuable insights into the metabolic processes and pathways occurring in lung tissue. This approach holds great potential for understanding lung disease, identifying biomarkers and developing targeted therapies to improve respiratory health. In this research collaboration, the analysis will be supported by machine learning techniques for risk assessment in PH.

Runtime: 01.04.2022 – 01.06.2024
Partner:  Medical University Graz
Funding: Commissioned project